JP2007531728A - 癌の処置のための５，１０−メチレンテトラヒドロ葉酸の使用 - Google Patents
癌の処置のための５，１０−メチレンテトラヒドロ葉酸の使用 Download PDFInfo
- Publication number
- JP2007531728A JP2007531728A JP2007506303A JP2007506303A JP2007531728A JP 2007531728 A JP2007531728 A JP 2007531728A JP 2007506303 A JP2007506303 A JP 2007506303A JP 2007506303 A JP2007506303 A JP 2007506303A JP 2007531728 A JP2007531728 A JP 2007531728A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- anticancer drug
- additional anticancer
- dosage
- fluorouracil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 236
- 238000011282 treatment Methods 0.000 title claims abstract description 174
- 201000011510 cancer Diseases 0.000 title claims abstract description 146
- QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 title claims abstract description 54
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims abstract description 575
- 229960002949 fluorouracil Drugs 0.000 claims abstract description 555
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 353
- 238000000034 method Methods 0.000 claims abstract description 353
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 327
- 231100000419 toxicity Toxicity 0.000 claims abstract description 114
- 230000001988 toxicity Effects 0.000 claims abstract description 114
- 239000000203 mixture Substances 0.000 claims abstract description 36
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 238
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 238
- 235000008191 folinic acid Nutrition 0.000 claims description 238
- 239000011672 folinic acid Substances 0.000 claims description 238
- 229960001691 leucovorin Drugs 0.000 claims description 238
- 229940002612 prodrug Drugs 0.000 claims description 129
- 239000000651 prodrug Substances 0.000 claims description 129
- 239000003814 drug Substances 0.000 claims description 104
- 229940079593 drug Drugs 0.000 claims description 102
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 99
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 72
- 229960004117 capecitabine Drugs 0.000 claims description 72
- 229960001756 oxaliplatin Drugs 0.000 claims description 51
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 51
- 229960005277 gemcitabine Drugs 0.000 claims description 46
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 46
- 239000003112 inhibitor Substances 0.000 claims description 44
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 42
- 102000004127 Cytokines Human genes 0.000 claims description 35
- 206010009944 Colon cancer Diseases 0.000 claims description 32
- 108090000695 Cytokines Proteins 0.000 claims description 32
- 238000001990 intravenous administration Methods 0.000 claims description 32
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 32
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 31
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 30
- 239000007924 injection Substances 0.000 claims description 30
- 238000002347 injection Methods 0.000 claims description 30
- 229960004768 irinotecan Drugs 0.000 claims description 30
- 230000009870 specific binding Effects 0.000 claims description 30
- 206010006187 Breast cancer Diseases 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 27
- 102000039446 nucleic acids Human genes 0.000 claims description 27
- 150000007523 nucleic acids Chemical class 0.000 claims description 27
- -1 pent cyclohexyl-5'-deoxy-5-fluorocytidine Chemical compound 0.000 claims description 27
- 208000026310 Breast neoplasm Diseases 0.000 claims description 26
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 claims description 26
- 229940127089 cytotoxic agent Drugs 0.000 claims description 26
- 229940043355 kinase inhibitor Drugs 0.000 claims description 23
- 229960004857 mitomycin Drugs 0.000 claims description 23
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 23
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 238000009472 formulation Methods 0.000 claims description 22
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 22
- 201000002528 pancreatic cancer Diseases 0.000 claims description 22
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 22
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 21
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 21
- 229960004397 cyclophosphamide Drugs 0.000 claims description 21
- 206010017758 gastric cancer Diseases 0.000 claims description 21
- 229940088597 hormone Drugs 0.000 claims description 21
- 239000005556 hormone Substances 0.000 claims description 21
- 201000011549 stomach cancer Diseases 0.000 claims description 21
- 102000029749 Microtubule Human genes 0.000 claims description 20
- 108091022875 Microtubule Proteins 0.000 claims description 20
- 229940100198 alkylating agent Drugs 0.000 claims description 20
- 239000002168 alkylating agent Substances 0.000 claims description 20
- 230000000340 anti-metabolite Effects 0.000 claims description 20
- 229940100197 antimetabolite Drugs 0.000 claims description 20
- 239000002256 antimetabolite Substances 0.000 claims description 20
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 20
- 239000003102 growth factor Substances 0.000 claims description 20
- 210000004688 microtubule Anatomy 0.000 claims description 20
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 20
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 19
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 16
- 229960003668 docetaxel Drugs 0.000 claims description 16
- 229960002066 vinorelbine Drugs 0.000 claims description 16
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 16
- 229960004679 doxorubicin Drugs 0.000 claims description 15
- GFFXZLZWLOBBLO-ASKVSEFXSA-N tezacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 GFFXZLZWLOBBLO-ASKVSEFXSA-N 0.000 claims description 15
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 14
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 14
- 201000010536 head and neck cancer Diseases 0.000 claims description 14
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 14
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 13
- 229960004316 cisplatin Drugs 0.000 claims description 13
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 12
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 12
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 12
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 12
- 229960001904 epirubicin Drugs 0.000 claims description 12
- 102000005962 receptors Human genes 0.000 claims description 12
- 108020003175 receptors Proteins 0.000 claims description 12
- 229930012538 Paclitaxel Natural products 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 11
- 239000002955 immunomodulating agent Substances 0.000 claims description 11
- 229940121354 immunomodulator Drugs 0.000 claims description 11
- 229960001592 paclitaxel Drugs 0.000 claims description 11
- 150000003384 small molecules Chemical class 0.000 claims description 11
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 11
- 229960004528 vincristine Drugs 0.000 claims description 11
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 11
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 11
- 229960000397 bevacizumab Drugs 0.000 claims description 10
- 229960005395 cetuximab Drugs 0.000 claims description 10
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 9
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 9
- 201000010881 cervical cancer Diseases 0.000 claims description 9
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 claims description 8
- 229950006410 tezacitabine Drugs 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 7
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 7
- 201000004101 esophageal cancer Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 14
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 14
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 14
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 12
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 12
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 claims 12
- MMBZCFJKAQZVNI-VPENINKCSA-N 4-amino-5,6-difluoro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound FC1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 MMBZCFJKAQZVNI-VPENINKCSA-N 0.000 claims 7
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 7
- 229960003048 vinblastine Drugs 0.000 claims 7
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 7
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 6
- 229940123429 VEGFR tyrosine kinase inhibitor Drugs 0.000 claims 6
- 210000004204 blood vessel Anatomy 0.000 claims 6
- 229940121647 egfr inhibitor Drugs 0.000 claims 6
- 230000002584 immunomodulator Effects 0.000 claims 6
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 4
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 4
- 230000004083 survival effect Effects 0.000 abstract description 43
- 230000004614 tumor growth Effects 0.000 abstract description 16
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 238000011277 treatment modality Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 111
- 108010022394 Threonine synthase Proteins 0.000 description 49
- 102000005497 Thymidylate Synthase Human genes 0.000 description 49
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 46
- 230000001093 anti-cancer Effects 0.000 description 45
- 235000019152 folic acid Nutrition 0.000 description 45
- 239000011724 folic acid Substances 0.000 description 45
- 229940014144 folate Drugs 0.000 description 43
- 241000699666 Mus <mouse, genus> Species 0.000 description 39
- 229940120638 avastin Drugs 0.000 description 28
- 238000002648 combination therapy Methods 0.000 description 25
- 238000011580 nude mouse model Methods 0.000 description 25
- 239000000890 drug combination Substances 0.000 description 24
- 230000004580 weight loss Effects 0.000 description 24
- 229940053867 xeloda Drugs 0.000 description 22
- 210000000440 neutrophil Anatomy 0.000 description 18
- 241000699660 Mus musculus Species 0.000 description 17
- 238000002512 chemotherapy Methods 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 15
- 238000011394 anticancer treatment Methods 0.000 description 15
- 238000001802 infusion Methods 0.000 description 15
- 238000001959 radiotherapy Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 230000000259 anti-tumor effect Effects 0.000 description 12
- 230000003190 augmentative effect Effects 0.000 description 12
- 239000003560 cancer drug Substances 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 11
- 229960001614 levamisole Drugs 0.000 description 11
- 238000009104 chemotherapy regimen Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000011269 treatment regimen Methods 0.000 description 9
- 102000001554 Hemoglobins Human genes 0.000 description 8
- 108010054147 Hemoglobins Proteins 0.000 description 8
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
- 150000001875 compounds Chemical group 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000011275 oncology therapy Methods 0.000 description 8
- 231100000440 toxicity profile Toxicity 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 description 7
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000001772 blood platelet Anatomy 0.000 description 7
- 230000000973 chemotherapeutic effect Effects 0.000 description 7
- 230000003862 health status Effects 0.000 description 7
- 108091008039 hormone receptors Proteins 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 229960000485 methotrexate Drugs 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000009395 breeding Methods 0.000 description 6
- 230000001488 breeding effect Effects 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 229940022353 herceptin Drugs 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 229960001674 tegafur Drugs 0.000 description 6
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 6
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 5
- 206010025327 Lymphopenia Diseases 0.000 description 5
- 238000004159 blood analysis Methods 0.000 description 5
- 238000011284 combination treatment Methods 0.000 description 5
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 5
- 238000001325 log-rank test Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 231100001023 lymphopenia Toxicity 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229930192392 Mitomycin Natural products 0.000 description 4
- 206010028116 Mucosal inflammation Diseases 0.000 description 4
- 206010059440 Platelet toxicity Diseases 0.000 description 4
- 108010020346 Polyglutamic Acid Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 4
- 229960001467 bortezomib Drugs 0.000 description 4
- 229960004562 carboplatin Drugs 0.000 description 4
- 190000008236 carboplatin Chemical compound 0.000 description 4
- 229960005243 carmustine Drugs 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 229940082789 erbitux Drugs 0.000 description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 4
- 229940080856 gleevec Drugs 0.000 description 4
- 231100001156 grade 3 toxicity Toxicity 0.000 description 4
- 238000005534 hematocrit Methods 0.000 description 4
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011221 initial treatment Methods 0.000 description 4
- 229940084651 iressa Drugs 0.000 description 4
- 201000002364 leukopenia Diseases 0.000 description 4
- 231100001022 leukopenia Toxicity 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 4
- 208000004235 neutropenia Diseases 0.000 description 4
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 4
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 4
- 231100000201 platelet toxicity Toxicity 0.000 description 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 231100000057 systemic toxicity Toxicity 0.000 description 4
- 229960001603 tamoxifen Drugs 0.000 description 4
- 229940120982 tarceva Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010043554 thrombocytopenia Diseases 0.000 description 4
- 229960000303 topotecan Drugs 0.000 description 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- 229950000578 vatalanib Drugs 0.000 description 4
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 3
- 238000000729 Fisher's exact test Methods 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 201000010927 Mucositis Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 206010070863 Toxicity to various agents Diseases 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 3
- 235000008207 calcium folinate Nutrition 0.000 description 3
- 239000011687 calcium folinate Substances 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 231100000026 common toxicity Toxicity 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 231100000226 haematotoxicity Toxicity 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940047122 interleukins Drugs 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 229920002643 polyglutamic acid Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010023644 Lacrimation increased Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 2
- 206010050283 Tumour ulceration Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 229940045276 gemcitabine 1000 mg Drugs 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000004317 lacrimation Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 description 1
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BZRPOJFQTMPGJK-UHFFFAOYSA-N carbamic acid;2-fluoropyrimidine Chemical compound NC(O)=O.FC1=NC=CC=N1 BZRPOJFQTMPGJK-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000004064 cosurfactant Substances 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 231100000355 lymphocytotoxic Toxicity 0.000 description 1
- 230000001391 lymphocytotoxic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000003039 myelosuppressive effect Effects 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000009118 salvage therapy Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000901 systemic toxic effect Toxicity 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55888904P | 2004-04-02 | 2004-04-02 | |
| US62547904P | 2004-11-04 | 2004-11-04 | |
| US65874505P | 2005-03-04 | 2005-03-04 | |
| PCT/US2005/011046 WO2005097086A2 (en) | 2004-04-02 | 2005-04-01 | Use of 5,10-methylene tetrahydrofolate for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007531728A true JP2007531728A (ja) | 2007-11-08 |
| JP2007531728A5 JP2007531728A5 (enExample) | 2008-05-01 |
Family
ID=35125596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506303A Pending JP2007531728A (ja) | 2004-04-02 | 2005-04-01 | 癌の処置のための５，１０−メチレンテトラヒドロ葉酸の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070280944A1 (enExample) |
| EP (1) | EP1740182A2 (enExample) |
| JP (1) | JP2007531728A (enExample) |
| AU (1) | AU2005231436A1 (enExample) |
| CA (1) | CA2561952A1 (enExample) |
| IL (1) | IL178261A0 (enExample) |
| WO (1) | WO2005097086A2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015504080A (ja) * | 2012-01-20 | 2015-02-05 | アイソフォル・メディカル・エービー | Ｅｇｆｒ阻害剤と組み合わせたテトラヒドロフォレート |
| JP2020531490A (ja) * | 2017-08-24 | 2020-11-05 | イソフォル メディカル アクティエボラーグ | ５−フルオロウラシルに基づく化学療法における［６ｒ］−ｍｔｈｆ、有効な葉酸代替物 |
| JP2021510140A (ja) * | 2018-01-05 | 2021-04-15 | アイソフォル・メディカル・エービー | 大腸癌及び転移性大腸癌を治療する方法 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009152228A2 (en) * | 2008-06-10 | 2009-12-17 | Yale University | Use of the combination of phy906 and a tyrosine kinase inhibitor as a cancer treatment regimen |
| ES2373867T3 (es) * | 2007-03-02 | 2012-02-09 | The University Of Wollongong | Composiciones y procedimientos para el suministro de agentes anticancerosos. |
| WO2008109349A1 (en) * | 2007-03-06 | 2008-09-12 | Adventrx Pharmaceuticals, Inc. | Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine |
| CA2738755C (en) * | 2008-09-26 | 2018-11-06 | Universite D'angers | Individual 5-fluorouracile dose optimization in folfiri treatment |
| CA2738753C (en) * | 2008-09-26 | 2018-11-06 | Universite D'angers | Individual 5-fluorouracile dose optimization in folfox treatment |
| EP2617422A1 (en) * | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate |
| WO2018065446A1 (en) * | 2016-10-05 | 2018-04-12 | Isofol Medical Ab | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
| EP3305318A1 (en) * | 2016-10-05 | 2018-04-11 | Isofol Medical AB | [6r]-5,10-methylenetetrahydrofolate in 5-fluorouracil based chemotherapy |
| WO2018065445A1 (en) * | 2016-10-05 | 2018-04-12 | Isofol Medical Ab | [6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy |
| EP3446703A1 (en) * | 2017-08-24 | 2019-02-27 | Isofol Medical AB | 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy |
| CN110430896A (zh) | 2017-02-14 | 2019-11-08 | 伊索弗尔医药公司 | 用于增加血浆2′-脱氧尿苷(dUrd)和胸苷酸合成酶抑制的方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5534519A (en) * | 1990-05-11 | 1996-07-09 | University Of Southern California | 5,10,-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent |
| WO2002070008A1 (en) * | 2001-03-02 | 2002-09-12 | Imclone Systems Incorporated | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
-
2005
- 2005-04-01 EP EP05732160A patent/EP1740182A2/en not_active Withdrawn
- 2005-04-01 JP JP2007506303A patent/JP2007531728A/ja active Pending
- 2005-04-01 AU AU2005231436A patent/AU2005231436A1/en not_active Abandoned
- 2005-04-01 US US10/594,850 patent/US20070280944A1/en not_active Abandoned
- 2005-04-01 WO PCT/US2005/011046 patent/WO2005097086A2/en not_active Ceased
- 2005-04-01 CA CA002561952A patent/CA2561952A1/en not_active Abandoned
-
2006
- 2006-09-21 IL IL178261A patent/IL178261A0/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5534519A (en) * | 1990-05-11 | 1996-07-09 | University Of Southern California | 5,10,-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent |
| WO2002070008A1 (en) * | 2001-03-02 | 2002-09-12 | Imclone Systems Incorporated | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015504080A (ja) * | 2012-01-20 | 2015-02-05 | アイソフォル・メディカル・エービー | Ｅｇｆｒ阻害剤と組み合わせたテトラヒドロフォレート |
| US9675617B2 (en) | 2012-01-20 | 2017-06-13 | Isofol Medical Ab | Tetrahydrofolates in combination with EGFR-inhibitors |
| JP2020531490A (ja) * | 2017-08-24 | 2020-11-05 | イソフォル メディカル アクティエボラーグ | ５−フルオロウラシルに基づく化学療法における［６ｒ］−ｍｔｈｆ、有効な葉酸代替物 |
| JP7356411B2 (ja) | 2017-08-24 | 2023-10-04 | イソフォル メディカル アクティエボラーグ | ５－フルオロウラシルに基づく化学療法における［６ｒ］－ｍｔｈｆ、有効な葉酸代替物 |
| JP2021510140A (ja) * | 2018-01-05 | 2021-04-15 | アイソフォル・メディカル・エービー | 大腸癌及び転移性大腸癌を治療する方法 |
| JP7258759B2 (ja) | 2018-01-05 | 2023-04-17 | アイソフォル・メディカル・エービー | 大腸癌及び転移性大腸癌を治療する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005097086A2 (en) | 2005-10-20 |
| IL178261A0 (en) | 2006-12-31 |
| WO2005097086A3 (en) | 2006-05-18 |
| US20070280944A1 (en) | 2007-12-06 |
| EP1740182A2 (en) | 2007-01-10 |
| AU2005231436A1 (en) | 2005-10-20 |
| CA2561952A1 (en) | 2005-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2127652B1 (en) | Method for treating cancer using anticancer agent in combination | |
| JP2020059713A (ja) | 膠芽腫治療のための併用療法 | |
| JP2007531728A (ja) | 癌の処置のための５，１０−メチレンテトラヒドロ葉酸の使用 | |
| EP3042669B1 (en) | Antitumor agent and antitumor effect enhancer | |
| TW200838875A (en) | Combination therapy with angiogenesis inhibitors | |
| EP3735267B1 (en) | Adminsitration of multiple boluses of [6r] mthf in a 5-fluorouracil-based chemotherapy | |
| TWI772354B (zh) | 在基於5-氟尿嘧啶的化療中[6r]-亞甲基四氫葉酸的多次推注施用 | |
| JP7122256B2 (ja) | 血漿２’－デオキシウリジン（ｄＵｒｄ）の増加およびチミジル酸合成酵素阻害のための方法 | |
| JP2014533277A (ja) | 固形腫瘍治療のための併用薬物療法 | |
| Garland et al. | A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors | |
| WO2021080421A1 (en) | Novel drug combinations for treatment of a carcinoma | |
| WO2019016928A1 (ja) | がん細胞の代謝の特異性に基づく新規抗悪性腫瘍剤 | |
| JP6174044B2 (ja) | Ｅｇｆｒ阻害剤と組み合わせたテトラヒドロフォレート | |
| KR102032933B1 (ko) | 고령이나 말기의 암환자를 치료 또는 경감하기 위한 의약 조성물 | |
| JP2021526161A (ja) | 癌治療のための方法及び医薬組成物 | |
| Fujitani et al. | Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer | |
| Camella et al. | Emerging role of capecitabine in gastric cancer | |
| Ueda et al. | Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer | |
| KR20070019725A (ko) | 암치료에 사용되는 5,10-메틸렌 테트라하이드로폴레이트의용도 | |
| Ricart et al. | Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors | |
| JP2016104703A (ja) | 抗腫瘍剤 | |
| JP7414230B2 (ja) | 抗血液悪性腫瘍薬 | |
| Melichar et al. | Urinary neopterin in patients with metastatic colon cancer treated with patupilone | |
| Takahashi et al. | Feasibility Study of Synchronized Intra-aortic Chemotherapy for Stage IV and Recurrent Gastric Cancer Localized in the Abdominal Cavity | |
| HK40014587A (en) | Methods for treating colorectal and metastatic colorectal cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080314 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080314 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110516 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111110 |